Table 1.
Patient characteristics of the entire cohort, sarcopenic patients and non-sarcopenic patients.
| Characteristics | Entire Cohort | Sarcopenic | Non-sarcopenic | p-Value |
|---|---|---|---|---|
| n = 38 (%) | n = 10 (26.3%) | n = 28 (73.7%) | ||
| Median age at diagnosis (IQR) | 64.5 (56.3–72.3) | 76.5 (70.3–80.5) | 59.5 (52.3–70) | < 0.001 |
| Median SMI (IQR) | 56.4 (49.2–65.6) | 48 (42.9–50.2) | 60.7 (55.3–67) | < 0.001 |
| Median PMI (IQR) | 7.4 (6.2–8.4) | 6.9 (6.1–7.6) | 7.7 (6.6-9) | 0.127 |
| Low PMI, n (%) | 20 (52.6%) | 7 (70%) | 13 (46.4%) | 0.200 |
| Median VSR (IQR) | 1.1 (0.7–1.6) | 1.5 (1.2–2.1) | 1 (0.6–1.4) | 0.022 |
| High VSR, n (%) | 12 (31.6%) | 6 (60%) | 6 (21.4%) | 0.024 |
| Median VFI (IQR) | 76 (42.6–97.4) | 86.6 (66.6–99) | 70.6 (39.6–96.3) | 0.220 |
| Median SFI (IQR) | 59.4 (41.2–76.3) | 60.6 (40.4–82.8) | 55.4 (40.5–76.7) | 0.791 |
| High VO, n (%) | 27 (71.1%) | 9 (90%) | 18 (64.3%) | 0.124 |
| pT-stage, n (%) | ||||
| pCis | 4 (10.5%) | 0 (0%) | 4 (14.3%) | 0.513 |
| pT1 | 14 (36.8%) | 3 (30%) | 10 (35.7%) | |
| pT2 | 10 (26.3%) | 3 (30%) | 7 (24.9%) | |
| pT3 | 10 (26.3%) | 4 (40%) | 6 (21.4%) | |
| pN-stage, n (%) | ||||
| pN0 | 21 (55.3%) | 4 (40%) | 17 (60.7%) | 0.593 |
| pN1 | 6 (15.8%) | 2 (20%) | 4 (14.3%) | |
| pN2 | 7 (18.4%) | 2 (20%) | 5 (17.9%) | |
| pN3 | 4 (10.5%) | 2 (20%) | 2 (7.1%) | |
| cM-stage, n (%) | 3 (7.9%) | 0 (0%) | 3 (10.7%) | 0.281 |
| Median BMI (IQR) | 27.9 (24.6–31.6) | 27.8 (25.2–30.3) | 28.6 (24.5–31.7) | 0.740 |
| BMI, n (%) | ||||
| Underweight (< 18.5) | 0 (0%) | 0 (0%) | 0 (0%) | 0.181 |
| Normal (18.5–24.9) | 11 (28.9%) | 2 (20%) | 9 (32.1%) | |
| Overweight (25–29.9) | 14 (36.8%) | 6 (60%) | 8 (28.6%) | |
| Obese (30–34.9) | 13 (43.2%) | 2 (20%) | 11 (39.3%) | |
| Phimosis, n (%) | 18 (47.3%) | 6 (60%) | 12 (42.8%) | 0.351 |
| ASA-Score, n (%) | ||||
| 1 | 6 (15.8%) | 2 (20%) | 4 (14.3%) | 0.277 |
| 2 | 19 (49.9%) | 3 (30%) | 16 (57.1%) | |
| 3 | 13 (34.2%) | 5 (50%) | 8 (28.6%) | |
| Smoker, n (%) | 12 (31.6%) | 3 (30%) | 9 (32.1%) | 0.900 |
| Cancer localization, n (%) | ||||
| Foreskin | 2 (5.3%) | 0 (0%) | 2 (7.14%) | 0.156 |
| Glans | 23 (60.5%) | 4 (40%) | 19 (67.9%) | |
| Shaft | 8 (21.1%) | 4 (40%) | 4 (14.3%) | |
| Multilocular | 5 (13.2%) | 2 (20%) | 3 (10.7%) | |
| Diabetes mellitus, n (%) | 7 (18.4%) | 2 (20%) | 5 (17.9%) | 0.881 |
| Private insurance | 11 (28.9%) | 3 (30%) | 8 (28.6%) | 0.932 |
| Alcohol abuse | 4 (10.4%) | 2 (20%) | 2 (7.1%) | 0.255 |
| Chemotherapy, n (%) | 10 (26.3%) | 8 (80%) | 2 (7.14%) | 0.882 |
| CCI | ||||
| 0 | 4 (10.5%) | 0 (0%) | 4 (14.3%) | 0.206 |
| 1–2 | 13 (34.2%) | 1 (10%) | 12 (42.8%) | 0.060 |
| 3–4 | 14 (36.8%) | 5 (50%) | 9 (32.1%) | 0.315 |
| ≥ 5 | 7 (18.4%) | 4 (40%) | 3 (10.7%) | 0.040 |
| LND | ||||
| None | 12 (13.6%) | 2 (20%) | 10 (35.7%) | 0.359 |
| Modified | 11 (28.9%) | 2 (20%) | 9 (32.1%) | 0.467 |
| Radical | 5 (13.2%) | 1 (10%) | 4 (14.3%) | 0.731 |
| Pelvin | 10 (26.3%) | 5 (50%) | 5 (17.9%) | 0.048 |
n = count of patients (percentage); IQR, interquartile range; SMI, skeletal muscle index; PMI, psoas muscle index; VSR, visceral-to-subcutaneous fat ratio; VFI, visceral fat index; SFI, subcutaneous fat index; VO, visceral obesity; pT-stage, pathological Tumor stage; pN-stage, pathological nodal classification; cM-stage, clinical metastases classification; BMI, body mass index; ASA, American Society of Anesthesiologists. CCI, Charlson comorbidity index; LND, lymph node dissection; p < 0.05 is considered statistically significant.